Bayer Gamunex immunoglobulin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bayer's intravenous human immunoglobulin Gamunex clears FDA Aug. 27 for primary humoral immunodeficiency and to raise platelet counts in idiopathic thrombocytopenic purpura to prevent bleeding. Bayer is touting its differentiated manufacturing process. For IGIV products, "the specifics of the manufacturing process, such as Bayer [Biological Products'] caprylate/chromatography purification, have a direct impact on the quality of an IGIV product," the firm said. FDA has previously advised healthcare providers to disregard manufacturer statements suggesting superiority of certain IGIV products over others...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.